Results 141 to 150 of about 407,552 (296)

ROS‐Responsive Nanoparticle Delivery of Dexmedetomidine Protects the Gut Vascular Barrier After Intestinal Ischemia/Reperfusion via the HDAC‐H3K27ac‐TCF4 Axis

open access: yesAdvanced Science, EarlyView.
A low dose of dexmedetomidine, delivered by ROS‐responsive nanoparticles, preferentially accumulates in the ischemic intestine and restores gut vascular barrier integrity after ischemia/reperfusion injury. This nanoparticle‐based strategy prevents bacterial translocation and liver damage without cardiorespiratory side effects, working through HDAC ...
Hu‐Fei Zhang   +10 more
wiley   +1 more source

SAV1 in Cooperation With FKBP52 Participates in Implantation

open access: yesAdvanced Science, EarlyView.
The MST‐SAV1 complex modulates FKBP52 phosphorylation to fine‐tune PR activity, ensuring timely uterine transition to receptivity under estrogen signaling for implantation. Stromal SAV1 scaffolds MST1/2‐mediated FKBP52 phosphorylation via noncanonical Hippo to promote PR activity.
Yuhan Shao   +10 more
wiley   +1 more source

Sonogenetics Nanomedicine Activates the cGAS‐STING Pathway for Immunotherapy of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
A HER3‐targeted sonogenetic lipid nanoparticle platform is developed for triple‐negative breast cancer therapy. An AI‐designed miniprotein inhibits HER3 signaling, while TRPV4 and NFAT‐responsive IL‐15 plasmids enable ultrasound‐controlled calcium signaling and cytokine expression. The system induces Ca2+ overload, ROS generation, mitochondrial damage,
Junya Song   +6 more
wiley   +1 more source

Isocyanate‐Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3‐Mediated Extracellular Matrix Remodeling and cGAS‐STING Pathway Activation in Bladder Cancer

open access: yesAdvanced Science, EarlyView.
A series of melatonin‐conjugated platinum(IV) prodrugs was functionalized with isocyanate chains (compounds 5‒12). MP‐12C (compound 11) was identified as the lead candidate, with optimal potency and safety. MP‐12C exhibited greater efficacy than cisplatin by increasing intracellular uptake, reshaping the extracellular matrix, activating the cGAS‐STING ...
Linhui Wang   +18 more
wiley   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

open access: yesAdvanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen   +10 more
wiley   +1 more source

Restores Aβ Clearance by Overcoming PCSK9–LRP1 Dysregulation and TRIB3‐Mediated Autophagy Blockade in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
PCSK9 upregulation in cerebrovascular endothelial cells and microglia destabilizes the Aβ transporter LRP1, while TRIB3‐associated autophagy blockade further limits intracellular Aβ degradation. A RAP‐modified tea‐polyphenol nanoparticle co‐delivers siPCSK9 and siTRIB3 to restore LRP1‐mediated Aβ efflux and autophagy‐dependent degradation, reducing Aβ ...
Jie Miao   +8 more
wiley   +1 more source

Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review. [PDF]

open access: yesRMD Open
Matucci-Cerinic C   +5 more
europepmc   +1 more source

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

open access: yesAdvanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He   +6 more
wiley   +1 more source

Autoimmune Hemolytic Anemia Following Intravenous Immunoglobulin in Kawasaki Disease. [PDF]

open access: yesCureus
Pastrana Echevarria I   +4 more
europepmc   +1 more source

A Multi‐Targeting Chimeric Antigen Receptor‐T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Lina Wang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy